NCT05017948 (AGING) is a NA clinical trial of Risk score based intervention in Iatrogenic Disease, sponsored by Rutgers, The State University of New Jersey.

Who is sponsoring NCT05017948?

NCT05017948 is sponsored by Rutgers, The State University of New Jersey.

What drugs are being tested in NCT05017948?

Interventions in NCT05017948: Risk score based intervention.

What condition does NCT05017948 study?

NCT05017948 studies Iatrogenic Disease, Risk Reduction.

Is NCT05017948 still recruiting?

NCT05017948 is currently completed. Last updated 14 November 2024.

Last reviewed 2024-11-14 · How we verify

NCT05017948: AGING

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alleviating Geriatric Inpatients' Medication-related Iatrogenesis

Completed NA Last updated 14 November 2024

What this trial tests

NA trial testing Risk score based intervention in Iatrogenic Disease in 60 participants. Completed in 1 November 2023.

Timeline

15 September 2021

Primary endpoint
1 May 2023

1 November 2023

Quick facts

Lead sponsor	Rutgers, The State University of New Jersey
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	60
Start date	15 September 2021
Primary completion	1 May 2023
Estimated completion	1 November 2023
Sites	1 location across United States

Drugs / interventions tested

Risk score based intervention

Conditions studied

Iatrogenic Disease — all drugs for Iatrogenic Disease →
Risk Reduction — all drugs for Risk Reduction →

Sponsor

Rutgers, The State University of New Jersey

Who can join

Adults 18 to 90, any sex, with Iatrogenic Disease or Risk Reduction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the MedWise Risk Score™ (MWRS™), a holistic approach to quantifying the risk of a patient's medication regimen. High risk patients will be identified at hospital discharge. Targeted interventions will be made to reduce their MWRS™ with a 30-day follow up. The hypothesis being tested is that a reduction in MWRS™ will lead to reduced 30-day readmission.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Rutgers, The State University of New Jersey trials

Trials by the same sponsor.

NCT07243886 — Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD) · NA · not yet recruiting
NCT06955130 — Lactate and Glycerol Contribution to Gluconeogenesis · NA · not yet recruiting
NCT06822010 — SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma · Phase 2 · not yet recruiting
NCT07525011 — Comparative Study of Denture Fabrication Techniques · NA · not yet recruiting
NCT06834204 — Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05017948 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rutgers, The State University of New Jersey
Last refreshed: 14 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05017948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing